Transaction DateRecipientSharesTypePriceValue
10th November 2020Raymond J Land3,446Open or private sale$36.77$126,709.42
30th October 2020Thomas Finnerty666Payment by withholding$32.62$21,724.92
16th October 2020Richard Hague10,546Payment by withholding$1.07$11,284.22
8th October 2020Richard Hague2,563Payment by withholding$1.12$2,870.56
1st October 2020Susan L N Vogt14,133Grant/award etc.$0.00
28th September 2020Richard Hague5,283Payment by withholding$1.04$5,494.32
3rd September 2020John B Iii Henneman9,310Grant/award etc.$0.00
3rd September 2020Stephen Richard9,310Grant/award etc.$0.00
6th August 2020Richard Hague8,545Payment by withholding$1.60$13,672.00
5th August 2020John B Iii Henneman10,000Open or private sale$15.00$150,000.00
Anika Therapeutics
Anika Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company. The company develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.


Ticker: ANIK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 898437
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $117 M (-25%)
Marketable Securities, Current: $28 M (0%)
Inventory, Net: $46 M (0%)
Assets, Current: $221 M (-5%)
Property, Plant and Equipment, Net: $53 M (3%)
Other Assets, Noncurrent: $13 M (79%)
Assets: $441 M (33%)
Accounts Payable, Current: $6 M (60%)
Liabilities, Current: $28 M (71%)
Other Liabilities, Noncurrent: $843 Th (136%)
Common Stock, Value, Issued: $142 Th (0%)
Common Stock, Shares, Issued: $14 Th (0%)
Additional Paid in Capital, Common Stock: $51 M (3%)
Retained Earnings (Accumulated Deficit): $244 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $6 M (-1%)
Stockholders' Equity (Parent): $288 M (0%)
Liabilities and Equity: $441 M (33%)
Revenue: $31 M (0%)
Cost of Revenue: $17 M (-45%)
Research and Development: $5 M (-57%)
Operating Income/Loss: $10 M (290%)
Provision for income taxes: $2 M (0%)
EPS (basic): $0.54 (315%)
EPS (diluted): $0.54 (315%)